Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 0

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 0
---
TABLE OF CONTENTS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14AINFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

| Filed by the Registrant                    |     | ☒ |
| Filed by a party other than the Registrant |     | ☐ |

Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |

| ☒ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| ☐ | Soliciting Material Pursuant to § 240.14a-12 |

| Vera Therapeutics, Inc.                                                 |
| (Name of Registrant as Specified in Its Charter)                        |
| N/A                                                                     |
| (Name of Person(s) Filing Proxy Statement if other than the Registrant) |

Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required |

| ☐ | Fee paid previously with preliminary materials |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

TABLE OF CONTENTS

VERA THERAPEUTICS, INC. 2000 Sierra Point Parkway, Suite 1200 Brisbane, California 94005 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On May 14, 2025 Dear Stockholder: You are cordially invited to attend the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Vera Therapeutics, Inc., a Delaware corporation (the “Company”). The Annual Meeting will be held on Wednesday, May 14, 2025, at 8:00 a.m. (Pacific Time). The Annual Meeting will be held through a live webcast at www.virtualshareholdermeeting.com/VERA2025. You will not be able to attend the meeting in person. The Annual Meeting is being held for the following purposes:

| 1. | To elect the three Class I directors named herein to hold office until the Company’s 2028 annual meeting of stockholders. |

| 3. | To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this Proxy Statement. |

|